Biomarker for ovarian and endometrial cancer: hepcidin

US7510842B2 · kind B2 · utility

Assignees

• VERMILLION, INC. · US
• The John Hopkins University · US
• The Board of Regents of the University of Texas System · US

Inventors

• Valdimir Podust · Fremont, US
• Zhen Zhang · Dayton, US
• Eric T. Fung · Austin, US
• Robert C. Bast, Jr. · Houston, US
• Daniel W. Chan · Clarksville, US
• Jin Song · Brea, US

Key dates

• Filing date: Mar 10, 2006
• Grant date: Mar 31, 2009
• Expiry date: Mar 10, 2026

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2500/00
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying ovarian cancer status as well as endometrical cancer status in a patient. In particular, it has been found that hepcidin is a biomarker for both ovarian cancer and endometrial cancer and that a panel of biomarkers, including hepcidin, transthyretin and optionally other markers are useful to classify a subject sample as ovarian cancer or non-ovarian cancer. The biomarkers can be detected by SELDI mass spectrometry.